Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol

Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence,...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23361
Acceso en línea:
https://doi.org/10.1186/s13643-019-1067-8
https://repository.urosario.edu.co/handle/10336/23361
Palabra clave:
Antibiotic agent
Atovaquone
Azithromycin
Ciprofloxacin
Clarithromycin
Clindamycin
Cotrimoxazole
Dapsone
Doxycycline
Erythromycin
Lincomycin
Macrolide
Methotrexate
Minocycline
Miokamycin
Nifurtimox
Pyrimethamine
Rifabutin
Spiramycin
Sulfadoxine
Sulfafurazole
Sulfamerazine
Sulfonamide
Tetracycline
Blurred vision
Chorioretinitis
Eye inflammation
Genetic heterogeneity
Human
Intraocular pressure
Leukocyte count
Meta analysis
Ocular toxoplasmosis
Optic disk
Outcome assessment
Priority journal
Quality control
Randomized controlled trial (topic)
Recurrent disease
Review
Systematic review
Visual acuity
Visual impairment
Anti-bacterial agents
Toxoplasma
Uveitis
ocular
Toxoplasmosis
Rights
License
Abierto (Texto Completo)
id EDOCUR2_ff554c1eeba627e24f61456576bd8189
oai_identifier_str oai:repository.urosario.edu.co:10336/23361
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
title Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
spellingShingle Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
Antibiotic agent
Atovaquone
Azithromycin
Ciprofloxacin
Clarithromycin
Clindamycin
Cotrimoxazole
Dapsone
Doxycycline
Erythromycin
Lincomycin
Macrolide
Methotrexate
Minocycline
Miokamycin
Nifurtimox
Pyrimethamine
Rifabutin
Spiramycin
Sulfadoxine
Sulfafurazole
Sulfamerazine
Sulfonamide
Tetracycline
Blurred vision
Chorioretinitis
Eye inflammation
Genetic heterogeneity
Human
Intraocular pressure
Leukocyte count
Meta analysis
Ocular toxoplasmosis
Optic disk
Outcome assessment
Priority journal
Quality control
Randomized controlled trial (topic)
Recurrent disease
Review
Systematic review
Visual acuity
Visual impairment
Anti-bacterial agents
Toxoplasma
Uveitis
ocular
Toxoplasmosis
title_short Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
title_full Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
title_fullStr Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
title_full_unstemmed Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
title_sort Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
dc.subject.keyword.spa.fl_str_mv Antibiotic agent
Atovaquone
Azithromycin
Ciprofloxacin
Clarithromycin
Clindamycin
Cotrimoxazole
Dapsone
Doxycycline
Erythromycin
Lincomycin
Macrolide
Methotrexate
Minocycline
Miokamycin
Nifurtimox
Pyrimethamine
Rifabutin
Spiramycin
Sulfadoxine
Sulfafurazole
Sulfamerazine
Sulfonamide
Tetracycline
Blurred vision
Chorioretinitis
Eye inflammation
Genetic heterogeneity
Human
Intraocular pressure
Leukocyte count
Meta analysis
Ocular toxoplasmosis
Optic disk
Outcome assessment
Priority journal
Quality control
Randomized controlled trial (topic)
Recurrent disease
Review
Systematic review
Visual acuity
Visual impairment
Anti-bacterial agents
Toxoplasma
Uveitis
topic Antibiotic agent
Atovaquone
Azithromycin
Ciprofloxacin
Clarithromycin
Clindamycin
Cotrimoxazole
Dapsone
Doxycycline
Erythromycin
Lincomycin
Macrolide
Methotrexate
Minocycline
Miokamycin
Nifurtimox
Pyrimethamine
Rifabutin
Spiramycin
Sulfadoxine
Sulfafurazole
Sulfamerazine
Sulfonamide
Tetracycline
Blurred vision
Chorioretinitis
Eye inflammation
Genetic heterogeneity
Human
Intraocular pressure
Leukocyte count
Meta analysis
Ocular toxoplasmosis
Optic disk
Outcome assessment
Priority journal
Quality control
Randomized controlled trial (topic)
Recurrent disease
Review
Systematic review
Visual acuity
Visual impairment
Anti-bacterial agents
Toxoplasma
Uveitis
ocular
Toxoplasmosis
dc.subject.keyword.eng.fl_str_mv ocular
Toxoplasmosis
description Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s).
publishDate 2019
dc.date.created.spa.fl_str_mv 2019
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:01:24Z
dc.date.available.none.fl_str_mv 2020-05-26T00:01:24Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1186/s13643-019-1067-8
dc.identifier.issn.none.fl_str_mv 20464053
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23361
url https://doi.org/10.1186/s13643-019-1067-8
https://repository.urosario.edu.co/handle/10336/23361
identifier_str_mv 20464053
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationIssue.none.fl_str_mv No. 1
dc.relation.citationTitle.none.fl_str_mv Systematic Reviews
dc.relation.citationVolume.none.fl_str_mv Vol. 8
dc.relation.ispartof.spa.fl_str_mv Systematic Reviews, ISSN:20464053, Vol.8, No.1 (2019)
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067883921&doi=10.1186%2fs13643-019-1067-8&partnerID=40&md5=2bd89c5ab5587fe47ba397b376f65979
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv BioMed Central Ltd.
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/7e02f3d5-8aed-4181-84a3-48a9cc239920/download
https://repository.urosario.edu.co/bitstreams/900d75d3-4962-4776-b545-69aa747812cd/download
https://repository.urosario.edu.co/bitstreams/9601aba4-196b-4608-9637-3088a03397e1/download
bitstream.checksum.fl_str_mv 5bfdd9fe1ae94d4ce52d2056695ab3ee
edea5be84ca2d3a196b19e795114d98c
a47399ef30356150d8d84c6d2eda2757
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167517780770816
spelling 029ab59e-5b59-42e3-b8d4-199bcc26eacfc2ac824b-123b-454c-8797-737a529d00dea373ad2e-cce5-4069-8f4c-7175dab885959e1c8ba4-0a0a-4f6e-bf5f-cc59d16a78fb26f8d9d7-47f2-40d2-bb34-5e40e1ad5504e945c156-e98e-4a6d-a727-d211c305742b3e98e801-ced5-4690-a65d-a3f6bb7e6104de1d6a3b-18f8-494f-84c9-ad0594da5d4dd975d6cb-a9d8-4221-a9a9-3de14928a5ec517013556002020-05-26T00:01:24Z2020-05-26T00:01:24Z2019Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s).application/pdfhttps://doi.org/10.1186/s13643-019-1067-820464053https://repository.urosario.edu.co/handle/10336/23361engBioMed Central Ltd.No. 1Systematic ReviewsVol. 8Systematic Reviews, ISSN:20464053, Vol.8, No.1 (2019)https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067883921&doi=10.1186%2fs13643-019-1067-8&partnerID=40&md5=2bd89c5ab5587fe47ba397b376f65979Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAntibiotic agentAtovaquoneAzithromycinCiprofloxacinClarithromycinClindamycinCotrimoxazoleDapsoneDoxycyclineErythromycinLincomycinMacrolideMethotrexateMinocyclineMiokamycinNifurtimoxPyrimethamineRifabutinSpiramycinSulfadoxineSulfafurazoleSulfamerazineSulfonamideTetracyclineBlurred visionChorioretinitisEye inflammationGenetic heterogeneityHumanIntraocular pressureLeukocyte countMeta analysisOcular toxoplasmosisOptic diskOutcome assessmentPriority journalQuality controlRandomized controlled trial (topic)Recurrent diseaseReviewSystematic reviewVisual acuityVisual impairmentAnti-bacterial agentsToxoplasmaUveitisocularToxoplasmosisAntibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocolarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Feliciano-Alfonso, John E.Vargas-Villanueva, AndrésMarín, María AlejandraTriviño, LauraCarvajal, NataliaMoreno, ManuelaLuna, TatianaLopez de Mesa, ClaraMuñoz-Ortiz, Julianade-la-Torre, AlejandraORIGINALs13643-019-1067-8.pdfapplication/pdf611441https://repository.urosario.edu.co/bitstreams/7e02f3d5-8aed-4181-84a3-48a9cc239920/download5bfdd9fe1ae94d4ce52d2056695ab3eeMD51TEXTs13643-019-1067-8.pdf.txts13643-019-1067-8.pdf.txtExtracted texttext/plain33703https://repository.urosario.edu.co/bitstreams/900d75d3-4962-4776-b545-69aa747812cd/downloadedea5be84ca2d3a196b19e795114d98cMD52THUMBNAILs13643-019-1067-8.pdf.jpgs13643-019-1067-8.pdf.jpgGenerated Thumbnailimage/jpeg4278https://repository.urosario.edu.co/bitstreams/9601aba4-196b-4608-9637-3088a03397e1/downloada47399ef30356150d8d84c6d2eda2757MD5310336/23361oai:repository.urosario.edu.co:10336/233612022-05-02 07:37:15.965658https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co